乳腺癌是妇女中所有癌症类型中导致死亡的第二大原因。它的性质高度异质性，意味着肿瘤具有不同的形态，即使在患有相同类型肿瘤的人中也存在异质性。由于不同类型乳腺癌的变异性，已经发展了几种分期和分类系统。由于高度异质性，个体化治疗成为一种新策略。三阴性乳腺癌（TNBC）是所有乳腺癌亚型中约占10% -15%。TNBC是指乳腺癌的亚型，其中细胞不表达雌激素受体，孕激素受体或人类表皮生长因子受体（ER，PR和HER）。TNBC的肿瘤具有多样化的遗传标记和预后指标。我们在Cancer Cell Line Encyclopedia（CCLE）和Genomics of Drug Sensitivity in Cancer（GDSC）数据库中使用人类乳腺癌细胞系和药物敏感性数据来寻找潜在药物。我们采用三种不同的机器学习方法评估6种对TNBC细胞系具有预测能力的有效药物。然后，根据这些标记物在乳腺癌中的参与程度进行初步筛选，并利用Cleveland数据库的数据进行放射性抗性测试。观察到Panobinostat、PLX4720、Lapatinib、Nilotinib、Selumetinib和Tanespimycin是对TNBC细胞系具有疗效的6种药物。我们可以鉴定出可能用于已批准药物的潜在衍生物。仅有一种标记物（SETD7）对短名单中的所有六种药物敏感，而另外两种标记物（SRARP和YIPF5）对放射线和药物都敏感。此外，我们没有发现任何TNBC的放射性抗性标记物。所提出的生物标记物和药物敏感性分析将为未来的临床研究提供潜在的候选人。Copyright © 2023 Kaushik and Zhao.

Breast cancer is the second leading cause of cancer death in women among all cancer types. It is highly heterogeneous in nature, which means that the tumors have different morphologies and there is heterogeneity even among people who have the same type of tumor. Several staging and classifying systems have been developed due to the variability of different types of breast cancer. Due to high heterogeneity, personalized treatment has become a new strategy. Out of all breast cancer subtypes, triple-negative breast cancer (TNBC) comprises ∼10%-15%. TNBC refers to the subtype of breast cancer where cells do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptors (ERs, PRs, and HERs). Tumors in TNBC have a diverse set of genetic markers and prognostic indicators. We scanned the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC) databases for potential drugs using human breast cancer cell lines and drug sensitivity data. Three different machine-learning approaches were used to evaluate the prediction of six effective drugs against the TNBC cell lines. The top biomarkers were then shortlisted on the basis of their involvement in breast cancer and further subjected to testing for radion resistance using data from the Cleveland database. It was observed that Panobinostat, PLX4720, Lapatinib, Nilotinib, Selumetinib, and Tanespimycin were six effective drugs against the TNBC cell lines. We could identify potential derivates that may be used against approved drugs. Only one biomarker (SETD7) was sensitive to all six drugs on the shortlist, while two others (SRARP and YIPF5) were sensitive to both radiation and drugs. Furthermore, we did not find any radioresistance markers for the TNBC. The proposed biomarkers and drug sensitivity analysis will provide potential candidates for future clinical investigation.Copyright © 2023 Kaushik and Zhao.